Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193 % ...

The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.

BioMarin Pharmaceutical (NASDAQ: BMRN) reported its third-quarter earnings after market close Monday, and they were good ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks.

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Stocks to Buy with Exponential Growth Heading into 2026.

Three pharma companies that have delivered the highest average 5-year ROCE are all into manufacturing the same type of products. Explore more to know what is driving these niche pharma players.

Arjun and Preethi discuss the impact of product review cycles on pharma stocks, focusing on Dr. Reddy's recent challenges.